A pair of Teflon-coated wires scraped bare at the ends was connected to a stimulator with isolated output for field stimulation of the tissue. Stimuli were 2 msec in duration or less, and current was 1.5-2 times threshold. Purkinje cells were impaled with glass microelectrodes filled with 3 M KCl selected for tip resistances of 10-20 Mfl. The microelectrodes were connected through silver-silver chloride connections to a WPI (World Precision Instruments, New Haven, Conn.) model 750 operational amplifier with variable input capacitance. The bath was grounded through a similar 3 M KCl-silver-silver chloride junction. The amplified transmembrane potential signal was displayed on one channel of a dual timebase oscilloscope (model 5113, Tektronix Inc., Beaverton, Ore.) and recorded on a strip-chart recorder (model 2400, Gould Instruments Inc., Cleveland). The signal from the amplifier and a sawtooth signal (200 V/sec) were input into an analog differentiator whose output was linear in the 100-1,000 V/sec range. The differentiated phase zero of the action potential and the calibration signal also were displayed on the oscilloscope at a faster sweep. The oscilloscope screen was photographed and the following action potential characteristics were derived from off-line digitized tracings: takeoff potential, action potential amplitude, overshoot, and APD at 50% repolarization (APD50) and at 90% repolarization (APD90). Maximum upstroke slope of phase zero (Vmax) was determined directly from the oscilloscope screen and the photographed records.
All tendons first were stimulated at a basic cycle length (CL) of 500-1,000 msec for 20-30 minutes to ensure stable action potential characteristics. Baseline action potential recordings were obtained at CL 1,000, 4,000, and 8,000 msec, allowing a minimum of 60 seconds at each CL. The effective refractory period was determined by inserting extra stimuli every eighth action potential while stimulating at CL 1,000 msec (10-20-msec decrements). Fibers with spontaneous automaticity at CL<4,000 msec were not used, and fibers with spontaneous automaticity at CL between 4,000 and 8,000 msec were used to assess the electrophysiological actions of cromakalim alone at CL 1,000 and 4,000.
After baseline data were obtained, fibers were exposed to action potential-prolonging interventions while stimulation was continued at CL 1,000 msec. These interventions included quinidine (3-10 ,uM) ; the 4-[(methylsulfonyl)amino]benzamide analogue of procainamide, sematilide29 (CK 1752a; 10 uM); or CsCl (3-10 mM). After 60-90 minutes of exposure to one of these agents, data were obtained again at each CL (1,000, 4,000, and 8,000 msec). If triggered activity then was present, cromakalim or pinacidil was added at increasing concentrations (15 minutes exposure at each concentration while maintaining superfusion with the action potential-prolonging agent) until no triggered activity was present at CL<8,000 msec. The effect of increasing concentrations of potassium channel activators on action potential characteristics also was assessed in preparations in which triggered activity was not elicited in the presence of action potential-prolonging agents. Also, the effects of a range of concentrations of cromakalim alone were assessed in a separate series of experiments. All data represent continuous impalements maintained throughout each experiment.
In Vivo Studies
New Zealand White rabbits (3.1-3.6 kg) were anesthetized with intravenous sodium pentobarbital (30-45 mg/kg delivered slowly over 15-30 minutes (Table 1) .
Data Analysis Action potential parameters as a function of drug concentration were compared by General Linear Models analysis of variance (ANOVA) testing (Number Crunching Statistical Systems, Ogden, Utah). The incidence of ventricular tachycardia among rabbits receiving pinacidil was compared with that in rabbits receiving placebo by two-tailed Fisher's exact test. Frequencies of ventricular ectopic beats were compared for the total 10-minute study period by Student's unpaired t test and at each 1-minute interval using General Linear Models ANOVA. Changes in blood pressure (precesium and postcesium) were compared by Student's paired t test. All values are given as mean±+ SD.
Results

In Vitro Studies
Dose-response experiments were performed in six fibers exposed to cromakalim alone (10-?-10`M).
As shown in Figure 1, In preparations pretreated with quinidine, cromakalim similarly shortened APD90 (Figure 2 ). At higher concentrations, quinidine-induced prolongation of APD90 was completely reversed, and APD90 was shortened by 10-`M cromakalim to 43±10% quinidine control at CL 4,000 msec. In contrast, quinidine-induced triggered activity was reversed by lower concentrations of cromakalim (10--10 -' M), at which no change in APD90 at the faster rates was found. This effect was observed in six of six preparations with quinidine-induced triggered activity exposed to cromakalim. Importantly, when triggered activity was abolished, quinidine-induced action potential prolongation was still evident at shorter CLs ( Figure 2 tilide. Each of these 17 preparations then was exposed to cromakalim (n=13) or pinacidil (n=4) and the triggering abolished. As described above, APD90 remained prolonged over baseline when this effect was observed (Figure 3) . At CL 1,000, baseline APD90 was 309±44 msec and was increased to 400±33 msec by the action prolonging intervention; treatment with cromakalim or pinacidil at a concentration sufficient to reverse triggering shortened APD90 to 397±67 msec (p<0.05 versus baseline).
The corresponding data at 4,000 msec were 362±95 msec (baseline), 549±100 msec (action potential prolongation), and 479±95 msec (cromakalim or pinacidil, p<0.05 versus baseline). The cromakalim concentrations that suppressed triggered activity were 10-7_10-5 M in the four sematilide experiments, 10-9_0-7 M in the six quinidine experiments, and 10-6 M in three cesium experiments. The concentrations of pinacidil that suppressed triggered activity were 3 x 10-7-3 x 10-5 M in three cesium experiments and 3 x 10`M in one quinidine experiment. Figure  4) . Two pinacidil-pretreated rabbits developed sustained ventricular tachycardia, two developed nonsustained ventricular tachycardia, and five had no ventricular tachycardia, compared with six, three, and zero, respectively, in vehicle-pretreated animals (p = 0.057).
Rabbits became markedly hypertensive after cesium infusion. However, blood pressure before the first cesium dose and the maximum response to cesium were similar in the pinacidil-pretreated and vehicle-pretreated animals. In vehicle-pretreated animals, cesium increased blood pressure from 93± 16 to 165+35 mm Hg, whereas in the pinacidilpretreated group, the precesium blood pressure was 98±10 mm Hg and rose to 168±18 mm Hg. Thus, at these doses, pinacidil exerted an antiarrhythmic effect without a major hypotensive action.
Discussion
These studies have demonstrated that the potassium channel activators pinacidil and cromakalim reversed abnormal automaticity induced by action potential-prolonging drugs in canine cardiac Purkinje fibers. Although this effect was predictable in view of the known action potential shortening effects of the drugs, it was interesting that action potentials remained prolonged at concentrations at which the antiarrhythmic effect was observed. Similarly, the cromakalim concentrations that exhibited this antiarrhythmic effect were an order of magnitude (or more) lower than those that significantly shortened APDI). These in vitro results suggest a protective '43 This study suggests that potassium channel activators may offer preferable alternative antihypertensive therapy for patients receiving QT-prolonging agents, at least to avoid the potassium-wasting effects of diuretics. Furthermore, our in vitro and in vivo data also suggest that arrhythmias related to abnormal repolarization may be suppressed by potassium channel activators. Thus, potassium channel activation also might prove beneficial in other subsets identified at risk for ventricular arrhythmias related to excessive QT prolongation, such as in patients with congenital long QT syndromes3'44 and possibly even in late postmyocardial infarction patients. 45 On the other hand, like any drug with electrophysiological activity, potassium channel activators also may potentiate arrhythmias under certain conditions, perhaps as a result of excessive or inhomogeneous shortening of refractoriness.
The effects of potassium channel activation on APD in these experiments was frequency dependent. At low concentrations, action potentials were shortened (and related arrhythmias reversed) at slow rates, whereas action potentials were not shortened at faster rates (Figures 2 and 3) . Thus, we speculate that an appropriate degree of potassium channel activation might control arrhythmias related to prolonged repolarization but not interfere with increased repolarization thought to contribute to arrhythmia suppression at faster rates (a class III action). Indeed, the occasional development of bradycardia-dependent torsade de pointes appears to be the single greatest liability of agents with pure class III properties. Otherwise, compared with sodium channel block, action potential prolongation as a therapeutic strategy produces less hemodynamic compromise,46 greater efficacy against sustained ventricular tachyarrhythmias related to recent coronary occlusion in dogs,47'48 and desirable effects on the energy required for defibrillation. 49 Hondeghem and Snyders50 recently have proposed that the "ideal" class III agent should produce its greatest action potential-prolonging actions at fast rates and have indicated that an open-state potassium channel blocker would satisfy this requirement. Until such agents are developed, the combination of available action potential-prolonging drugs with low-dose potassium channel activators may produce a similar desirable electrophysiological profile.
